Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Dec 19;14(12):e1007813.
doi: 10.1371/journal.pgen.1007813. eCollection 2018 Dec.

Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria

Affiliations
Meta-Analysis

Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria

Felix Day et al. PLoS Genet. .

Erratum in

  • Correction: Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria.
    Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, Kraft P, Lin N, Huang H, Broer L, Magi R, Saxena R, Laisk T, Urbanek M, Hayes MG, Thorleifsson G, Fernandez-Tajes J, Mahajan A, Mullin BH, Stuckey BGA, Spector TD, Wilson SG, Goodarzi MO, Davis L, Obermayer-Pietsch B, Uitterlinden AG, Anttila V, Neale BM, Jarvelin MR, Fauser B, Kowalska I, Visser JA, Andersen M, Ong K, Stener-Victorin E, Ehrmann D, Legro RS, Salumets A, McCarthy MI, Morin-Papunen L, Thorsteinsdottir U, Stefansson K; 23andMe Research Team; Styrkarsdottir U, Perry JRB, Dunaif A, Laven J, Franks S, Lindgren CM, Welt CK. Day F, et al. PLoS Genet. 2019 Dec 5;15(12):e1008517. doi: 10.1371/journal.pgen.1008517. eCollection 2019 Dec. PLoS Genet. 2019. PMID: 31805045 Free PMC article.

Abstract

Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology. Affected women frequently have metabolic disturbances including insulin resistance and dysregulation of glucose homeostasis. PCOS is diagnosed with two different sets of diagnostic criteria, resulting in a phenotypic spectrum of PCOS cases. The genetic similarities between cases diagnosed based on the two criteria have been largely unknown. Previous studies in Chinese and European subjects have identified 16 loci associated with risk of PCOS. We report a fixed-effect, inverse-weighted-variance meta-analysis from 10,074 PCOS cases and 103,164 controls of European ancestry and characterisation of PCOS related traits. We identified 3 novel loci (near PLGRKT, ZBTB16 and MAPRE1), and provide replication of 11 previously reported loci. Only one locus differed significantly in its association by diagnostic criteria; otherwise the genetic architecture was similar between PCOS diagnosed by self-report and PCOS diagnosed by NIH or non-NIH Rotterdam criteria across common variants at 13 loci. Identified variants were associated with hyperandrogenism, gonadotropin regulation and testosterone levels in affected women. Linkage disequilibrium score regression analysis revealed genetic correlations with obesity, fasting insulin, type 2 diabetes, lipid levels and coronary artery disease, indicating shared genetic architecture between metabolic traits and PCOS. Mendelian randomization analyses suggested variants associated with body mass index, fasting insulin, menopause timing, depression and male-pattern balding play a causal role in PCOS. The data thus demonstrate 3 novel loci associated with PCOS and similar genetic architecture for all diagnostic criteria. The data also provide the first genetic evidence for a male phenotype for PCOS and a causal link to depression, a previously hypothesized comorbid disease. Thus, the genetics provide a comprehensive view of PCOS that encompasses multiple diagnostic criteria, gender, reproductive potential and mental health.

PubMed Disclaimer

Conflict of interest statement

Members of the 23andMe Research team are employees of and hold stock or stock options in 23andMe, Inc. GT, UT, KS, and US are employees of deCODE genetics/Amgen Inc. MIM serves on advisory panels for Pfizer and NovoNordisk. MIM has received honoraria from Pfizer, NovoNordisk and EliLilly, and has received research funding from Pfizer, NovoNordisk, EliLilly, AstraZeneca, Sanofi Aventis, Boehringer Ingelheim, Merck, Roche, Janssen, Takeda, and Servier. JL has received consultancy fees from Danone, Metagenics inc., Titus Healthcare, Roche and Euroscreen. CW is a consultant for Novartis and has received UptoDate royalties.

Figures

Fig 1
Fig 1. Manhattan plot showing results of meta-analysis for PCOS status, adjusting for age.
The inverse log10 of the p value (-log10(p)) is plotted on the Y axis. The green dashed line designates the minimum p value for genome-wide significance (<5.0 x 10−8). Genome wide significant loci are denoted with a label showing the nearest gene to the index SNP at each locus. SNPs with p values ≤1.0x10-2 are not depicted.
Fig 2
Fig 2. Odds ratio of polycystic ovary syndrome (PCOS) as a function of diagnostic criteria applied.
The Y-axis specifies the diagnostic criteria and the X-axis indicates the odds ratio (OR) and 95% confidence intervals (CI) for PCOS (black circle and horizontal error bars). Data derived as follows: NIH = groups recruiting only NIH diagnostic criteria; NonNIH_Rotterdam = Rotterdam diagnostic criteria excluding the subset fulfilling NIH diagnostic criteria; Rotterdam+NIH = all groups except self-reported; self-reported = 23andMe; and combined = all groups. Specific OR’s [95% CI, 5% CI] are indicated on the right. rs804279 in the GATA4/NEIL2 locus demonstrates significant heterogeneity (Het P = 2.6x10-5). The * indicates statistically significant association for PCOS and the variant in that specific stratum.

Comment in

References

    1. Vink J.M., Sadrzadeh S., Lambalk C.B. & Boomsma D.I. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 91, 2100–4 (2006). 10.1210/jc.2005-1494 - DOI - PubMed
    1. Kahsar-Miller M.D., Nixon C., Boots L.R., Go R.C. & Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 75, 53–8 (2001). - PubMed
    1. Legro R.S., Driscoll D., Strauss J.F. 3rd, Fox J. & Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 95, 14956–60 (1998). - PMC - PubMed
    1. Jahanfar S., Eden J.A., Nguyen T., Wang X.L. & Wilcken D.E. A twin study of polycystic ovary syndrome and lipids. Gynecol Endocrinol 11, 111–7 (1997). - PubMed
    1. Jahanfar S., Eden J.A., Warren P., Seppala M. & Nguyen T.V. A twin study of polycystic ovary syndrome. Fertil Steril 63, 478–86 (1995). - PubMed

Publication types